Items Tagged ‘News Release’
November 25th, 2014 · Leave a Comment
By Sam Smith
ROCHESTER, Minn. — Before reaching for that daily antacid, you might consider what it’s doing to the trillions of bugs living in your gut. A new Mayo Clinic study in the open access journal Microbiome shows that people who regularly take proton pump inhibitors (PPIs) have less diversity among their gut bacteria, putting them at increased risk for infections like clostridium difficile and pneumonia, in addition to vitamin deficiencies and bone fractures.
MEDIA CONTACT: Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, Email: email@example.com
Journalists: Soundbites with Dr. DiBaise are available in the downloads. Read the rest of this entry »
Tags: Arizona News Release, bacteria, center for individualized medicine, Clostridium Difficile, genome, genomics, GERD, gut microbiome, gut microflora, John DiBaise, microbiome, Minnesota news release, News Release, nexium, nicholas chia, osteoporosis, pneumonia, prilosec, Proton Pump Inhibitors, vitamin b12, vitamin deficiency
November 19th, 2014 · Leave a Comment
By Brian Kilen
ROCHESTER, Minn. — Here are highlights from the November issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required. Include the following subscription information as your editorial policies permit: Visit http://www.healthletter.mayoclinic.com/ or call toll-free for subscription information, 1-800-333-9037, extension 9771. Full newsletter text: Mayo Clinic Health Letter November 2014 (for journalists only). Full special report text: Mayo Clinic Health Letter Special Report November 2014 (for journalists only).
New approaches for relief from irritable bowel syndrome
There are new approaches to manage the frustrating symptoms of irritable bowel syndrome (IBS), according to the November issue of Mayo Clinic Health Letter.
IBS is a common disorder of the large intestine (colon), characterized by abdominal pain that occurs before or along with diarrhea or constipation. Symptoms can vary widely. For many people, flares of diarrhea may last for a few days followed by periods of remission. Constipation may last for days or even months, along with intermittent diarrhea or normal bowel function. A small number of people with severe IBS have unbearable pain that is constant at times.
Multiple factors may contribute to the bowel dysfunction. The foundation of IBS therapy is developing lifestyle, exercise and diet changes that generally facilitate smooth bowel function. Treatment often includes working with a physician or other care provider to develop a plan for regular exercise and management of stress, anxiety and other psychological factors. Read the rest of this entry »
November 17th, 2014 · Leave a Comment
By Joe Dangor
ROCHESTER, Minn. — The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology.
"Ixazomib is an investigational, oral proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy," says Shaji Kumar, M.D., a hematologist at Mayo Clinic and lead author of the study. "While it is well known that a combination of bortezomib, lenalidomide and dexamethasone is highly effective in treating newly diagnosed multiple myeloma, we wanted to study the safety, tolerability and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma."
November 17th, 2014 · Leave a Comment
Boston — A molecule in the blood shows promise as a marker to predict whether individual rheumatoid arthritis patients are likely to benefit from biologic medications or other drugs should be tried, a Mayo Clinic-led study shows. The protein, analyzed in blood tests, may help avoid trial and error with medications, sparing patients treatment delays and unnecessary side effects and expense. The research is among several Mayo Clinic studies presented at the American College of Rheumatology annual meeting in Boston.
Researchers tested blood samples taken before rheumatoid arthritis treatment was given. The patients then were treated with anti-inflammatory biologic drugs, tumor necrosis factor-alpha inhibitors, a new class of medications used for rheumatoid arthritis. They found that a protein made by the immune system, type 1 interferon, appears to serve as a valid marker to tell whether individual rheumatoid arthritis patients will respond to biologics, or other medications should be tried.
Journalists: Sound bites of Dr. Niewold are available in the downloads below.
November 16th, 2014 · Leave a Comment
By Traci Klein
CHICAGO — Patients with active asthma — such as any use of asthma medications, and unscheduled office or emergency visits for asthma — are at a twofold risk of having a heart attack, according to Mayo Clinic research presented at the American Heart Association’s Scientific Sessions 2014.
Researchers compared 543 patients who had heart attacks with 543 non-heart attack patients of the same age and gender. These patients were treated at health care facilities in Rochester, Minnesota, between 2002 and 2006. The average age of patients was 67 years old, and 44 percent were women. Within the heart attack patient group, 81 patients had asthma, 44 of those with active asthma.
After controlling for traditional heart attack risk factors such as age, obesity, high blood pressure, smoking, diabetes and high cholesterol, a history of coronary heart disease, and conditions such as chronic obstructive pulmonary disease, results showed that patients with inactive asthma were not at an increased risk of heart attack, but those with active asthma were at a 70 percent risk, says Young Juhn, M.D., senior author and Mayo Clinic pediatric and adolescent physician and clinical epidemiologist. Read the rest of this entry »
November 15th, 2014 · Leave a Comment
By Joe Dangor
MIAMI — A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. The findings were part of the results of a Phase III clinical trial presented today at the Society for Neuro-Oncology’s 19th Annual Meeting in Miami by the study’s primary author Jan Buckner, M.D., deputy director, practice, at Mayo Clinic Cancer Center.
“On average, patients who received PCV lived 5.5 years longer than those who received radiation alone,” says Dr. Buckner. “These findings build on results published in the Journal of Clinical Oncology in 2012 and presented at the 2014 annual meeting of the American Society of Clinical Oncology, which showed that PCV given with radiation therapy at the time of initial diagnosis prolongs progression free-survival but not overall survival.”
Tags: and vincristine, ASCO 2014, brain cancer, CCNU, Chemotherapy, Dr Buckner, Glioma, jan buckner, Mayo Clinic Cancer Center, Minnesota news release, National Cancer Institute, News Release, procarbazine, Radiation Therapy, RTOG 9082, Society for NeuroOncology 2014
November 14th, 2014 · Leave a Comment
JACKSONVILLE, Fla. — The Mayo Clinic Board of Trustees welcomed Mary Sue Coleman, Ph.D., as a new public member at its quarterly meeting today.
Dr. Coleman is president emeritus of the University of Michigan, (U-M) an institution she led for 12 years before retiring in July 2014. Time magazine named her one of the nation’s “10 best college presidents,” and the American Council on Education honored her with its Lifetime Achievement Award. She previously was president of the University of Iowa.
As University of Michigan president, Dr. Coleman unveiled several major initiatives designed to impact on future generations of students, the intellectual life of the campus, and society at large. The initiatives focused on the interdisciplinary richness of the U-M, student residential life, the economic vitality of the state and nation, global engagement and the value of innovation and creativity. President Obama chose Dr. Coleman to help launch the Advanced Manufacturing Partnership, a national effort bringing together industry, universities and the federal government.
Click here for a bio of Dr. Mary Sue Coleman.
MEDIA CONTACT: Karl Oestreich, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org.
November 13th, 2014 · Leave a Comment
By Bob Nellis
ROCHESTER, Minn. — One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called TNF inhibitors. They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the balancing acts of medicine, the anti-inflammatory action of the drug also increases the risk for other conditions, in this case, a rare form of eye cancer, uveal melanoma. Mayo Clinic researchers make the case and alert physicians in an article in Mayo Clinic Proceedings.
Mayo researchers studied three patients — two women and a man — who were treated for inflammatory disease and developed melanoma tumors in one eye within a year to two of taking TNF inhibitors. While this type of condition is probably rare, according to the researchers, there might be an increased risk if the patient has a pre-existing nevus (freckle of the eye). The women had inflammatory bowel disease; the man had rheumatoid arthritis. The studies occurred between 2009 and 2013.
Researchers say that patients considered for treatment with TNF inhibitors should first be given an eye exam to determine eye health, and any with existing conditions, such as choroidal nevus (lesions on the eye), should be monitored regularly to determine if any issues are developing.
November 11th, 2014 · Leave a Comment
By Sam Smith
ROCHESTER, Minn. — A diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung, a Mayo Clinic study has found. For patients with multiple tumors, that distinction could mean the difference between early stage cancer that may be cured by surgery and incurable late-stage disease. The research is published this week in the Journal of Clinical Oncology.
“Unfortunately, distinguishing between independent primary tumors and metastasis is a frequent dilemma for pathologists” says Marie-Christine Aubry, M.D., a Mayo Clinic pathologist and co-principal author of the study. “We need better tests to help the clinician match the treatment approach to the patient’s individual needs.”
Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, email@example.com
Journalists: Soundbites with Dr. Wigle are in the downloads. Read the rest of this entry »
Tags: chromosomal rearrangements, Dennis Wigle, diagnostic test, DNA sequencing, Journal of Clinical Oncology, Lung Cancer, Mayo Clinic Cancer Center, Minnesota news release, News Release, squamous cell carcinoma
November 10th, 2014 · Leave a Comment
By Lynn Closway
PHOENIX—Mayo Clinic in Arizona, in collaboration with Phoenix Children’s Hospital, has begun treating pediatric patients with complex cancers, using a course of outpatient radiation therapy administered on Mayo’s Phoenix campus.
Phoenix Children’s Hospital refers pediatric patients to Mayo Clinic for radiation therapy who are experiencing brain tumors, leukemia, Wilms’ tumor, neuroblastomas, sarcomas and some solid tumors, according to Carol Davis, the Ambulatory Business Operations manager for Phoenix Children’s Center for Cancer and Blood Disorders. Children who are hospitalized at Phoenix Children’s Hospital are transported to Mayo via ambulance, while others come with their parents for the outpatient treatment.
Mayo and Phoenix Children’s Hospital have collaborated for a number of years on clinical programs, including pediatric bone marrow transplants and pediatric liver transplants. Radiation Oncology is yet another such collaboration, which maximizes the expertise of both Valley institutions.
Lynn Closway, Mayo Clinic, 480-301-4337, Closway.firstname.lastname@example.org
Stacy Dillier, Phoenix Children’s Hospital, 602-933-0824, Sdillier@phoenixchildrens.com